WHO ICTRP trial
Dasatinib very low dose for elderly CML patients
JPRN-jRCTs071180047 · Japan Primary Registries Network (JPRN) · Not Recruiting
Key facts
| Trial ID | JPRN-jRCTs071180047 |
|---|---|
| Public title | Dasatinib very low dose for elderly CML patients |
| Scientific title | A Multicenter Joint Phase II Clinical Study to Evaluate the Efficacy and Safety of Dasatinib Very Low Dose Therapy in Elderly Patients with Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia - DAVLEC |
| Primary sponsor | Kimura Shinya |
| Registry | Japan Primary Registries Network (JPRN) |
| Recruitment status | Not Recruiting |
| Study type | Interventional |
| Phase | 2 |
| Conditions | chronic-phase chronic myeloid leukemia |
| Interventions | Once-daily oral administration of dasatinib will be started at the dose of 20 mg. The treatment effect will be evaluated according to the European LeukemiaNet recommendations (ELN2013) at 3, 6, 9 and 12 months after initiation of treatment… |
| Registration date | Mar 14, 2019 |
| Target size | 50 |
| Secondary IDs | UMIN000024548 |
| Registry page | jrct.niph.go.jp |
At a glance
- Yes Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: